The data showed that the compounds demonstrated potent activity against the human-immunodeficiency virus, including non-nucleoside reverse transcriptase inhibitor (NNRTI)- resistant strains, with the potential for improved performance over current NNRTIs.
The compounds in this NNRTI series are potent against both wild-type and the most common NNRTI-resistant viruses and are more active than efavirenz (Sustiva, BMS) and nevirapine (Viramune, Boehringer-Ingelheim) against a broad panel of NNRTI-resistant clinical isolates.
Barry Quart, president and CEO of Ardea, said: “Our lead NNRTI, RDEA806, has shown the potential to match this profile and we are preparing to progress it into a Phase IIb trial later this quarter. An important part of our business strategy is to progress an additional next generation NNRTI into Phase I later this year.”